An integrated model of the transcriptome of HER2-positive breast cancer [PDF]
, 2013 Our goal in these analyses was to use genomic features from a test set of primary breast tumors to build an integrated transcriptome landscape model that makes relevant hypothetical predictions about the biological and/or clinical behavior of HER2 ...
Melissa Lau +65 more
core +1 more source
Molecular & Cellular Oncology, 2017 Insulin receptor substrate 4 (IRS4) belongs to a family of cytoplasmic docking proteins mediating signals from cell surface receptors to downstream effectors.
Gerjon J. Ikink, John Hilkens
doaj +1 more source
HER2-positive apocrine carcinoma of the breast: a population-based analysis of treatment and outcome. [PDF]
, 2022 Apocrine carcinoma of the breast (APO) expresses HER2 in 30-50% of cases. This study explored the clinicopathological features and outcome of HER2+/APO and matched HER2+/NST cohort. We used the SEER database to explore the cohorts.
Faruk Skenderi (6616190) +12 more
core +1 more source
Cardiac Safety of Trastuzumab on 185 Patients with HER2 Positive Breast Cancer
Zhongliu Fangzhi Yanjiu, 2018 Objective To analyze the cardiac safety of trastuzumab on HER2 positive breast cancer patients. Methods Trastuzumab was administrated every three weeks in 185 patients with HER2 positive breast cancer.
MENG Wenjing +3 more
doaj +1 more source
Anti‐proliferative effects of pentagamaboronon‐0‐sorbitol on HER2‐overexpressing breast cancer cells
Indonesian Journal of Biotechnology, 2022 HER2‐positive breast cancer is an aggressive form of the disease that is associated with poor prognosis and chemo‐resistance. As such, investigation continues into the development of a new HER2‐targeted drug for breast cancer. This study investigated the
Lailatul Qodria +3 more
doaj +1 more source
Trastuzumab (Herceptin (R)): Monoclonal antibody in the treatment of HER2/neu-overexpressing breast cancer in the metastatic and (neo)adjuvant situation [PDF]
, 2006 Trastuzumab (Herceptin (R)) is a humanized monoclonal antibody that specifically targets HER2/neu (human epidermal growth factor receptor-2) breast cancer cells, which are overexpressed in about 25-30% of breast carcinomas.
Bauerfeind, Ingo +7 more
core +1 more source
HER2-family signalling mechanisms, clinical implications and targeting in breast cancer.
, 2015 Approximately 20 % of human breast cancers (BC) overexpress HER2 protein, and HER2-positivity is associated with a worse prognosis. Although HER2-targeted therapies have significantly improved outcomes for HER2-positive BC patients, resistance to ...
John Crown (112358) +5 more
core +4 more sources
Systems analysis of drug-induced receptor tyrosine kinase reprogramming following targeted mono- and combination anti-cancer therapy [PDF]
, 2014 The receptor tyrosine kinases (RTKs) are key drivers of cancer progression and targets for drug therapy. A major challenge in anti-RTK treatment is the dependence of drug effectiveness on co-expression of multiple RTKs which defines resistance to single ...
Goltsov, Alexey +26 more
core +1 more source
HER2 and BARD1 Polymorphisms in Early HER2-Positive Breast Cancer Patients: Relationship with Response to Neoadjuvant Anti-HER2 Treatment [PDF]
, 2023 The addition to chemotherapy of anti-HER2 drugs such as trastuzumab or pertuzumab has improved outcomes in HER2-positive breast cancer patients. However, resistance to these drugs in some patients remains a major concern. This study examines the possible
Novillo Villajos, Apolonia +19 more
core +1 more source
Acta Dermato-Venereologica, 2023 is missing (Short communication)
Yui Hirano-Lotman +4 more
doaj +1 more source